ArticleOpen forum infectious diseases2026
One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials.
Amy Zheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.